Year :
2021
| Month :
February
| Volume :
15
| Issue :
2
| Page :
MC01 - MC05
Full Version
Effectiveness and Safety of Ginkgo biloba,
Vinpocetine and Piracetam as a Single
Agent and Fixed Dose Combination in
Patients with Subjective Tinnitus
Published: February 1, 2021 | DOI: https://doi.org/10.7860/JCDR/2021/48182.14589
Paul Mathai, Anu Chandran, Sourav Das
1. Assistant Professor, Department of Pharmacology, Malabar Medical College, Modakkallur, Calicut, Kerala, India.
2. Assistant Professor, Department of Pharmacology, Malabar Medical College, Modakkallur, Calicut, Kerala, India.
3. Physician, Department of Emergency, Amina Hospital, Ajman, United Arab Emirates.
Correspondence Address :
Dr. Paul Mathai,
Assistant Professor, Department of Pharmacology, Malabar Medical College,
Modakkallur, Calicut-673323, Kerala, India.
E-mail: mathaipaul69@gmail.com; pulsusparadoxus82@gmail.com
Abstract
Introduction: Owing to the lack of any standard treatment, subjective tinnitus can be debilitating, manifesting a varied population response to tinnitus management. There is, therefore, an unmet need to optimise the existing treatment options and generate data to help physicians provide the best possible care for individual patients.
Aim: To compare the effectiveness and safety of Ginkgo biloba, vinpocetine, and piracetam as a single agent and their Fixed Dose Combination (FDC) in patients with subjective tinnitus.
Materials and Methods: Patients with complaints of subjective tinnitus were enrolled in this longitudinal cohort, single centre study which was conducted at Outpatient Clinic of the ENT Department of Justice KS Hegde Charitable Hospital, Karnataka, India. Patients received one of the five treatments, oral route, three times a day, {group 1: Ginkgo biloba (40 mg); group 2: vinpocetine (5 mg); group 3: piracetam (400 mg); group 4: FDC of Ginkgo biloba (60 mg) and piracetam (400 mg); group 5: FDC of Ginkgo biloba (60 mg), piracetam (800 mg) and vinpocetine (5 mg)} and were followed-up for six weeks using a modified version of Tinnitus Handicap Inventory (THI) and Visual Analogue Scale (VAS), before and after the treatment. Data for safety were also recorded. The association between each attribute and the presence of tinnitus was assessed through chi-square tests.
Results: A total of 130 out of 149 enrolled patients completed the study. All the groups showed significant improvement in the severity of symptoms at the end of six weeks as assessed by the modified THI and VAS scores. The improvement was found to be better in group 5 than in other groups, which was evident from the percentage improvement at the end of the treatment compared to other groups. No adverse drug reactions were associated with any of the treatment groups.
Conclusion: Though all the drugs were found to be effective and safe in reducing the intensity of subjective tinnitus, FDC of Ginkgo biloba-piracetam-vinpocetine may be considered a better alternative than Ginkgo biloba-piracetam combination and Ginkgo biloba, piracetam, or vinpocetine as single agents.
Keywords
External acoustic stimulus, Tinnitus handicap inventory, Visual analogue scale
DOI: 10.7860/JCDR/2021/48182.14589
Date of Submission: Dec 19, 2020
Date of Peer Review: Jan 06, 2020
Date of Acceptance: Jan 16, 2021
Date of Publishing: Feb 01, 2021
AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. NA
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Dec 23, 2020
• Manual Googling: Jan 15, 2021
• iThenticate Software: Jan 21, 2021 (21%)
Etymology: Author Origin
|